Department of Cardiology, Koç University Hospital, Istanbul, Turkey.
Organ Transplant Center, Koç University Hospital, Istanbul, Turkey.
J Clin Ultrasound. 2022 Jul;50(6):749-755. doi: 10.1002/jcu.23234. Epub 2022 May 21.
Pulmonary complications are common in patients with liver cirrhosis. Devolopment of pulmonary hypertension (PH) is associated with a poor prognosis in these patients. Pulmonary arterial stiffness (PAS) is considered an early sign of pulmonary vascular remodeling. The aim of this study is to investigate PAS and compare it with right ventricular (RV) functions in patients with cirrhosis who are scheduled for liver transplantation.
The study included 52 cirrhosis patients (mean age 51.01 ± 12.18 years, male gender 76.9%) who were prepared for liver transplantation and 59 age and sex matched (mean age 51.28 ± 13.63 years, male gender 62.7%) healthy individuals. Patients with left ventricular ejection fraction (LVEF) less than 55%, ischemic heart disease, more than mild valvular heart disease, chronic pulmonary disease, congenital heart disease, rheumatic disease, moderate to high echocardiographic PH probability, rhythm or conduction disorders on electrocardiography were excluded from the study. In addition to conventional echocardiographic parameters, PAS value, pulmonary vascular resistance (PVR) and RV ejection efficiency was calculated by the related formulas with transthoracic echocardiography (TTE).
Demographic characteristics and cardiovascular risk factors of the groups were similar. PAS, PVR, and sPAP values were found to be significantly higher in the patient group (20.52 ± 6.52 and 13.73 ± 2.05; 1.43 ± 0.15 and 1.27 ± 0.14; 27.69 ± 3.91 and 23.37 ± 3.81 p < 0.001, respectively). RV FAC and RV Ee were significantly lower and RV MPI was significantly higher in the patient group (45.31 ± 3.85 and 49.66 ± 3.62, p < 0.001; 1.69 ± 0.35 and 1.85 ± 0.23, p = 0.005; 0.39 ± 0.07 and 0.33 ± 0.09, p = 0.001, respectively). PAS was significantly correlated with RV FAC and MPI (r = -0.423, p < 0.001; r = 0.301, p = 0.001, respectively).
Increased PAS in cirrhosis patients may be associated with early pulmonary vascular involvement. Evaluation of RV functions is important to determine the prognosis in these patients. FAC, MPI, and RV Ee measurements instead of TAPSE or RV S' may be more useful in demonstrating subclinical dysfunction. The correlation of PAS with RV FAC and MPI may indicate that RV subclinical dysfunction is associated with early pulmonary vascular remodeling in patients with liver cirrhosis.
肝硬化患者常发生肺部并发症。发展为肺动脉高压(PH)与这些患者的预后不良相关。肺动脉僵硬度(PAS)被认为是肺血管重塑的早期迹象。本研究旨在研究肝硬化患者的 PAS,并与准备进行肝移植的患者的右心室(RV)功能进行比较。
该研究纳入了 52 名肝硬化患者(平均年龄 51.01±12.18 岁,男性占 76.9%)和 59 名年龄和性别匹配的健康个体(平均年龄 51.28±13.63 岁,男性占 62.7%)。排除左心室射血分数(LVEF)<55%、缺血性心脏病、>轻度瓣膜性心脏病、慢性肺部疾病、先天性心脏病、风湿性疾病、中度至高度超声心动图 PH 可能性、心律失常或心电图传导障碍的患者。除了常规超声心动图参数外,还通过经胸超声心动图(TTE)计算 PAS 值、肺血管阻力(PVR)和 RV 射血效率。
两组的人口统计学特征和心血管危险因素相似。患者组的 PAS、PVR 和 sPAP 值显著升高(分别为 20.52±6.52 和 13.73±2.05、1.43±0.15 和 1.27±0.14、27.69±3.91 和 23.37±3.81,p<0.001)。患者组的 RV FAC 和 RV Ee 显著降低,RV MPI 显著升高(分别为 45.31±3.85 和 49.66±3.62,p<0.001;1.69±0.35 和 1.85±0.23,p=0.005;0.39±0.07 和 0.33±0.09,p=0.001)。PAS 与 RV FAC 和 MPI 显著相关(r=-0.423,p<0.001;r=0.301,p=0.001)。
肝硬化患者的 PAS 升高可能与早期肺血管受累有关。评估 RV 功能对于确定这些患者的预后很重要。FAC、MPI 和 RV Ee 测量值而不是 TAPSE 或 RV S'可能更有助于显示亚临床功能障碍。PAS 与 RV FAC 和 MPI 的相关性表明,肝硬化患者的 RV 亚临床功能障碍与早期肺血管重塑有关。